<DOC>
	<DOCNO>NCT01253694</DOCNO>
	<brief_summary>Treatment Ranibizumab residual diabetic edema patient fail response Bevacizumab .</brief_summary>
	<brief_title>Ranibizumab Rescue Therapy Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : 1 . Age &gt; 18 year 2 . Diagnosis diabetes mellitus ( type 1 2 ) 3 . Residual edema determine mean foveal thickness Spectralis OCT ( optical coherence tomography ) &gt; 300 micron leakage see FA baseline 4 . Clinical evidence retinal thickening due macular edema involve center macula , associate diabetic retinopathy . 5 . Previous history least 35 consecutive 1.25 mg intravitreal bevacizumab injection treatment diabetic macular edema ( consecutive injection administer 6 week apart ) . 6 . BCVA 20/3220/400 use Early Treatment Diabetic Retinopathy Study ( ETDRS ) 7 . Media clarity , pupillary dilation patient cooperation sufficient allow OCT test retinal photography 1 . Pregnancy ( positive pregnancy test ) know pregnant ; also premenopausal woman use adequate contraception . 2 . Participation another ocular investigation trial simultaneously . 3 . Systemic use antiVEGF within 3 month prior day 0 . 4 . Blood pressure &gt; 180/110 ( systolic 180 OR diastolic 110 ) 5 . Any condition , opinion investigator , would preclude participation study ( e.g . chronic alcoholism , drug abuse ) . 6 . Evidence vitreoretinal interface abnormality ocular exam OCT may contribute macular edema . 7 . An eye , investigator 's opinion , chance improve visual acuity follow resolution macular edema ( e.g . presence subretinal fibrosis , ischemic maculopathy geographic atrophy ) . 8 . Presence another ocular condition may affect visual acuity macular edema course study ( e.g . Agerelated Macular Degeneration , uveitis , IrvineGass ) . 9 . Evidence active neovascularization iris retina . 10 . Evidence central atrophy fibrosis study eye . 11 . Presence substantial cataract , one might decrease vision 3 line vision sometime study . 12 . History vitreous surgery study eye . 13 . History cataract surgery within 6 month enrollment . 14 . History YAG capsulotomy within 2 month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>edema</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>refractory</keyword>
</DOC>